146 related articles for article (PubMed ID: 23277061)
1. Insulin-like growth factor receptor type I as a target for cancer therapy.
Corvaia N; Beck A; Caussanel V; Goetsch L
Front Biosci (Schol Ed); 2013 Jan; 5(2):439-50. PubMed ID: 23277061
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor type I as a target for cancer therapy.
Goetsch L; Corvaïa N
Immunotherapy; 2009 Mar; 1(2):265-79. PubMed ID: 20635945
[TBL] [Abstract][Full Text] [Related]
3. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
[TBL] [Abstract][Full Text] [Related]
5. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
[TBL] [Abstract][Full Text] [Related]
6. A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers.
Adachi Y; Yamamoto H; Ohashi H; Endo T; Carbone DP; Imai K; Shinomura Y
World J Gastroenterol; 2010 Dec; 16(46):5779-89. PubMed ID: 21154998
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
[TBL] [Abstract][Full Text] [Related]
9. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cao L; Yu Y; Darko I; Currier D; Mayeenuddin LH; Wan X; Khanna C; Helman LJ
Cancer Res; 2008 Oct; 68(19):8039-48. PubMed ID: 18829562
[TBL] [Abstract][Full Text] [Related]
10. Targeting the insulin-like growth factor network in cancer therapy.
Heidegger I; Pircher A; Klocker H; Massoner P
Cancer Biol Ther; 2011 Apr; 11(8):701-7. PubMed ID: 21311212
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
12. Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation.
Mao Y; Shang Y; Pham VC; Ernst JA; Lill JR; Scales SJ; Zha J
J Biol Chem; 2011 Dec; 286(48):41852-41861. PubMed ID: 21994939
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
Wang Y; Hailey J; Williams D; Wang Y; Lipari P; Malkowski M; Wang X; Xie L; Li G; Saha D; Ling WL; Cannon-Carlson S; Greenberg R; Ramos RA; Shields R; Presta L; Brams P; Bishop WR; Pachter JA
Mol Cancer Ther; 2005 Aug; 4(8):1214-21. PubMed ID: 16093437
[TBL] [Abstract][Full Text] [Related]
14. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
15. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
[TBL] [Abstract][Full Text] [Related]
16. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics.
Christopoulos PF; Corthay A; Koutsilieris M
Cancer Treat Rev; 2018 Feb; 63():79-95. PubMed ID: 29253837
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a chimeric monoclonal antibody against the insulin-like growth factor-I receptor.
Zhang MY; Feng Y; Wang Y; Dimitrov DS
MAbs; 2009; 1(5):475-80. PubMed ID: 20065647
[TBL] [Abstract][Full Text] [Related]
18. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
19. Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer.
Han L; Zhang GF; Cheng YH; Zhao QC
Jpn J Clin Oncol; 2016 Dec; 46(12):1127-1134. PubMed ID: 27737962
[TBL] [Abstract][Full Text] [Related]
20. The decline and fall of the IGF-I receptor.
Baserga R
J Cell Physiol; 2013 Apr; 228(4):675-9. PubMed ID: 22926508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
